Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.06 --0%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
VIVE, ENSV, MDLM, More
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
VIVE, ENSV, MDLM, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $13.71 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Best Buy (BBY) Tops Q2 EPS by 12c, Offers Guidance
- Bernstein SocGen Group Reiterates Market Perform Rating on Bloom Energy Corp. (BE)
- Materialise NV (MTLS) Reports Q2 EPS of EUR0.06
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
